{"url_path":"/sec/lyel/8-k/2026-06-15/item-5-07","section_key":"item-5-07","section_title":"Item 5.07 Submission of Matters to a Vote of Security Holders.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-15","source_url":"https://www.sec.gov/Archives/edgar/data/1806952/0001193125-26-271071-index.html","accession_number":"0001193125-26-271071","cik":"0001806952","ticker":"LYEL","issuer_name":"Lyell Immunopharma, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1806952/0001193125-26-271071-index.html","primary_entity_key":"0001806952","primary_entity_name":"Lyell Immunopharma, Inc."},"word_count":360,"has_tables":true,"body_markdown":"Item 5.07. Submission of Matters to a Vote of Security Holders.\n\nOn June 10, 2026, Lyell Immunopharma, Inc. (the “Company”) virtually held its 2026 annual meeting of stockholders (the “Annual Meeting”). Present at the beginning of the Annual Meeting via remote communication or by proxy were the holders of 15,706,826 shares of common stock of the Company, representing 67.31% of the 23,332,254 shares of common stock outstanding as of the close of business on April 14, 2026, the record date for the Annual Meeting, and constituting a quorum for the transaction of business.\n\nAt the Annual Meeting, the Company’s stockholders voted on three proposals, each of which is described in more detail in the Company’s definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on April 24, 2026 (the “Proxy Statement”). The following is a brief description of each matter voted upon and the certified results, including the number of votes cast for or against each matter and, if applicable, the number of votes withheld, abstentions and broker non-votes with respect to each matter.\n\n \n\n \n1.\n\nTo elect the following Class II directors to hold office until the Company’s 2029 annual meeting of stockholders. The voting results were as follows:\n\n \n\nName\n\n  \nVotes For\n \n  \nVotes\nWithheld\n \n  \nBroker\nNon-Votes\n \n  \nTotal\n \n\nRichard Klausner, M.D.\n\n  \n \n12,177,913\n \n  \n \n99,627\n \n  \n \n3,429,286\n \n  \n \n15,706,826\n \n\nOtis Brawley, M.D.\n\n  \n \n11,866,210\n \n  \n \n411,330\n \n  \n \n3,429,286\n \n  \n \n15,706,826\n \n\nWilliam Rieflin\n\n  \n \n12,192,547\n \n  \n \n84,993\n \n  \n \n3,429,286\n \n  \n \n15,706,826\n \n\n \n\n \n2.\n\nTo ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results were as follows:\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstentions\n\n \n\nTotal\n\n15,674,347\n \n30,758\n \n1,721\n \n15,706,826\n\n \n\n \n3.\n\nTo approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. The voting results were as follows:\n\n \n\nVotes For\n\n \n\nVotes Against\n\n \n\nAbstentions\n\n \n\nBroker Non-Votes\n\n \n\nTotal\n\n11,860,218\n \n6,613\n \n410,709\n \n3,429,286\n \n15,706,826\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \n\n \nLyell Immunopharma, Inc.\n\nDate: June 15, 2026\n \n\n \nBy:\n \n\n/s/ Mark Meltz\n\n \n\n \n\n \nMark Meltz\n\n \n\n \n\n \nGeneral Counsel"}